Examples of using Immunic in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
SAN DIEGO, October 10, 2019- Immunic, Inc.
Active IND allows Immunic to proceed with Phase 2 clinical trial CALDOSE-1.
SC receives milestone payment from Immunic.
Immunic is planning to start a further Phase 2 clinical trial in Crohn's disease CD.
This IND approval marks a significant milestone for Immunic.
Since the beginning of 2017, we have been involved in Immunic Therapeutics AG with the IBG funds.
Immunic develops pharmaceuticals to treat chronic inflammatory diseases and autoimmune disorders; e.
Moreover, they could benefit from an inspiring keynote delivered by Dr Hella Kohlhof,CSO of Immunic Therapeutics, who recently closed one of Europe's largest ever Series A investment rounds.
Immunic has set out to demonstrate the effectiveness of its two lead projects in patients over the next three years.
Thanks to a very solid investment case andan excellent team, Immunic managed to win over an international consortium of renowned life sciences investors and experienced an impressive round of funding- even by international standards.
Immunic Reports Start of Enrollment into Clinical Phase 2 Study with IMU-838 in Patients with Ulcerative Coliti.
As a clinical stage company, Immunic delivers clinical proof-of-concept for best-in-class therapies of Th1 and Th17 mediated chronic inflammatory diseases.
Immunic was founded in April 2016 with the purpose to advance promising drug development projects to clinical proof-of-concept.
Planegg-Martinsried, Germany, September 5th, 2017- Immunic AG(Immunic Therapeutics), a clinical stage private biotech company in Martinsried near Munich, Germany, today announced that it has completed its Series A round of financing now totaling EUR 31.7 million of preferred stock financing.
Immunic is planning to start Phase 2 clinical trials in the two main inflammatory bowel disease(IBD) indications ulcerative colitis(UC) and Crohn's disease CD.
In addition, Immunic is preparing a second Phase 2 trial(CALDOSE-2), in patients with Crohn's disease which is planned to commence after receiving interim data from the UC trial.
Immunic, with headquarters in Planegg-Martinsried near Munich, Germany, is privately held and supported by several renowned sector investors.
Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.
Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.
April 26th, 2018- Immunic AG(Immunic Therapeutics), a clinical stage biotech company in Martinsried near Munich, Germany, today announced that it has started the clinical Phase 2 trial(CALDOSE-1) in patients with ulcerative colitis UC.
February 1 st, 2017- Immunic AG(Immunic Therapeutics), a recently founded private biotech company in Martinsried near Munich, Germany, today announced that it has expanded its Series A round of financing now totaling EUR 21.7 million of preferred stock financing.
Immunic AG is a young biotech company based in the Munich biotech hub Martinsried and Halle/Saale that develops pharmaceuticals in the immunology space, in particular for autoimmune diseases or diseases that have an important immunology component in their pathogenesis.
December 12th, 2017- Immunic AG(Immunic Therapeutics), a clinical stage biotech company in Martinsried near Munich, Germany, today announced that it has completed its clinical phase 1 program for IMU-838 exploring its pharmacokinetic properties, as well as its safety and tolerability.